On September 26, Pfizer Investment Co., Ltd. (referred to as Pfizer) and Shanghai Pharmaceuticals Holding Co., Ltd. (referred to as Shanghai Pharmaceuticals) signed a strategic cooperation framework agreement. The two parties will focus on the vaccine field, engaging in long-term collaboration in product promotion, the introduction of innovative products, and policy research.

Leveraging their respective strengths, they will explore strategies to deepen and enhance their partnership in the commercial promotion of vaccine products and accelerate the introduction of innovative products, along with thorough cooperation in policy research and capacity training. This effort aims to support the robust development of China's public health services and disease control efforts, ultimately aiding disease prevention and health improvement across all stages of life.

Jean-Christophe Pointeau, President of Pfizer China, stated: "The collaboration between Pfizer and Shanghai Pharmaceuticals will harness both parties' strengths to empower the promotion and dissemination of innovative vaccines scientifically, allowing internationally leading vaccines to benefit more people in China and significantly improve national health levels. This partnership aims to become a new productivity force in the reform of the disease control system, contributing to the realization of the 'Healthy China 2030' strategic goals."

Li Yongzhong, Executive Director and CEO of Shanghai Pharmaceuticals, remarked: "Under the guidance of favorable policies, the domestic biopharmaceutical industry is entering a 'fast track' of development, achieving comprehensive growth. We are pleased to partner with Pfizer to further improve the coverage and accessibility of innovative vaccines, enhance the quality of immunization services throughout the lifecycle, and establish a new model for equitable, systematic, and sustainable preventive immunization health services, benefiting more Chinese patients and contributing to the reform of China's healthcare system and the development of public health."
https://finance.eastmoney.com/a/202409273193403260.html